Australia has one of highest rates of asthma in the world. With a prevalence rate of 10% in Australia, asthma is a national health priority area.
The Australian Asthma Handbook defines asthma as chronic condition which can be controlled but not cured. The goals of good asthma control are to minimise day and night time symptoms, limitation of activity, airway narrowing, bronchodilator use and risk of adverse outcomes such as exacerbations.
A 2015 study by Reddel et al. surveyed 2,686 Australians with asthma aged over 16 years. The online study used the Asthma Control Test (ACT) and revealed that: 54.4% of participants were classified as ‘well controlled’, 22.7% of participants were ‘not well controlled’, 23.0% were ‘very poorly controlled’.
This interactive online learning activity is valued at 6 Hour(s) of continuing education.
Associate Professor Charlotte Hespe
MBBS (Hons), FRACGP, DCH (Lon), FAICD, GCUT (UNDA)
Head of General Practice and Primary Care Research,
University of Notre Dame Australia - School of Medicine, Sydney
Chair, RACGP NSW/ACT
Director, Central and Eastern Sydney PHN
Director, Glebe Family Medical Practice, NSW
Professor Matthew Peters
MD FRACP FThorSoc
Professor of Respiratory Medicine
Faculty of Medicine and Health Sciences
Concord Hospital NSW
Professor Sinthia Bosnic-Anticevich
B Pharm (Hons), PhD
Principal Research Fellow,
Woolcock Institute, University of Sydney, NSW
On completion of this program, participants will be better able to:
- Distinguish between the modes of action of benzodiazepines, benzodiazepine receptor agonists and more novel therapies to address sleep onset and maintenance
- Describe the role of novel therapies in the management of chronic insomnia
- Identify patients with insomnia who would be appropriate for switching to novel therapies
- Counsel patients regarding the potential risks associated with long term use of benzodiazepines and benzodiazepine receptor agonists(‘Z-drugs’), and how to switch from these drugs to novel therapies